Print this page    •   Back to Web version of article

International News
Trimeris Shares Increase 13% as Sales of Fuzeon Rise in Europe, Brazil; Analysts Predict Profit as Early as 2006

July 22, 2005

Shares of Durham, N.C.-based pharmaceutical company Trimeris on Wednesday rose by 13% -- closing at $12.75 per share, up $1.43 -- after the company reported second-quarter losses more favorable than analysts' predictions, the Raleigh News & Observer reports. Increases in sales of the company's antiretroviral drug Fuzeon in Europe and Brazil cut losses by 80% for the second quarter of 2005, and the company lost 14 cents per share, compared with a loss of 17 cents per share, as had been predicted by analysts at Thomson Financial. Sales of Fuzeon outside North America increased in the second quarter, accounting for more than half of the drug's $53.9 million in second-quarter sales. Analysts "believe things are beginning to look positive for Trimeris," Legg Mason analyst Edward Nash wrote in a research report following the release of the company's earnings report (Vollmer, Raleigh News & Observer, 7/21).

Back to other news for July 22, 2005


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art8963.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.